Bone Index wins award for most promising Nordic Life Science company

Finland offers excellent opportunities for health and life sciences R&D&I, as well as international partnerships.

Finnish company Bone Index has been named the most promising Nordic Life Science company at the Nordic Life Science Days event held in Stockholm, which attracted more than 570 companies from 26 countries. Bone Index has developed the world’s first pocket-sized diagnostic device for osteoporosis which makes it easier to screen patients in need of medication. The social costs of osteoporotic fractures in the EU region are estimated at 40 billion euros per year.


“The unique Bindex® device developed by the company identifies patients with osteoporosis quickly and easily. Up to now, the biggest problem has been the low rate of diagnosis, because it has only been possible to examine bone density in hospitals by means of an expensive X-ray scan, which subjects patients to a radiation dose,” says the Jussi Holopainen, Chairman of the Board of Directors at Bone Index.


VTT develops new in-body catheters and surgical instruments


Another good example of innovative R&D work conducted in Finland is a research project coordinated by VTT Technical Research Centre of Finland for developing a technology platform to enable advanced imaging, sensing and steering functions to be integrated into (sub)millimetre size in-body catheters and surgical instruments. The new technology can be used in emerging, complex, minimally invasive cardio-, neuro-, and peripheral vascular interventions.


Finnish companies involved in the project included Murata Finland (MFI), Okmetic ja Afore. According to VTT, the devices developed in the project will accelerate the paradigm shift from costly, burdensome surgical treatments to cost-effective and patient-friendly, minimally invasive interventions. The new technologies will improve patient outcomes and lower the tremendous economic and social cost of cardiovascular disease in society.


Sources: Bone Index, VTT